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A b s t r a c t  
 Inclusion complexes between leflunomide, a poorly water soluble antirheumatic drug, and HP-β-
cyclodextrin (HP-β-CD) were used to improve the solubility and dissolution rate of the drug. 
Leflunomide forms an inclusion complex with HP-β-CD both in aqueous and in solid state. Phase 
solubility profile indicated that the solubility of leflunomide significantly increased in the presence of 
HP-β-CD and was classified as AL-type, indicating the 1:1 stoichiometric inclusion complexes in 
aqueous medium. The solid complexes prepared by different methods such as physical mixture, co-
grinding method and freeze dried method in 1:1 and 1:2 molar ratio, were characterized by 
differential scanning calorimetry (DSC) and X-RD. The dissolution profiles of solid complexes were 
determined and compared with leflunomide alone and their physical mixture, different mediums such 
as simulated gastric fluid (pH 1.2) and simulated intestinal fluid (pH 7.4). The dissolution studies 
showed that, the freeze-dried complex exhibited higher dissolution rates than the drug, in the 
simulated gastric fluid (SGF pH 1.2) in 1:2 molar ratio.  
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Introduction 
From many years new chemical entities were discovered by the 
pharmaceutical industry. Out of these about 40% are poorly water 
soluble or lipophilic compounds. Not only these new drugs but 
also many existing drugs are also poorly water soluble, so they 
pose difficulties to the biopharmaceutical scientists in their 
formulation. [1,2] Oral delivery of poorly water-soluble drugs often 
results in low bioavailability since the rate-limiting step for 
absorption from the gastrointestinal tract is a significantly slower 
dissolution rate. Thus, many molecules that are biologically active 
in-vitro are ineffective in-vivo as a result of their limited solubility 
and slow rate of dissolution. Several techniques have been used 
to improve the solubility and dissolution rate of poorly water 
soluble drugs and among the possibilities, over recent years, the 
cyclodextrin and their derivatives have received considerable 
interest in the pharmaceutical field due to their potential to form 
complexes with a variety of drug molecules.  Pharmaceutical 
modification of the drug molecules by inclusion complexation with 
cyclodextrin has been extensively developed to improve solubility, 
dissolution rate, chemical stability, absorption and bioavailability 
of the poorly water soluble drugs and reduce side effect and 
toxicity of the drug. [3,4] The cyclodextrins (CDs) are cyclic 
oligosaccharides consisting of six, seven or eight                    
D-glucopyranose units (đ, β and γ CD) linked by (đ-1, 4) glycosidic 
bonds and arranged in a truncated cone shape structure. [5-7] 
These agents exhibit a hydrophilic exterior and a hydrophobic 
internal cavity in which drugs may form inclusion complexes, 
being trapped entirely or at least partially. [8, 9] Several driving 
forces have been proposed for the inclusion of CDs with 
substrates such as hydrogen binding, Van der Waals force, 
hydrophobic interaction and the release of „high energy water‰ 
molecules from the cavity, however, no covalent bonds exist 
between the CD and its guest. As a result of complex formation, 
the physicochemical properties of the guest molecules, such as 
solubility, thermal stability, melting point, chemical reactivity, 
spectroscopic and electrochemical properties will be changed. 
Out of three parent CDs, HP-β-cyclodextrin appears more useful 
as a pharmaceutical agent because of its complexing ability, 
cavity dimension, low cost, higher productive rate and other 
properties. The cavity size is suitable for common pharmaceutical 
drugs with molecular weights between 200 and 800 g mol-1. [10, 
11] 
 Leflunomide is a pyrimidine synthesis inhibitor indicates in adults 
for the treatment of active rheumatoid arthritis. Rheumatoid 
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arthritis is an auto immune disease characterized by high T-cell 
activity. Chemically it is 5-methyl-N-[4-(trifluoromethyl) phenyl]-4-
isoxazole carboxamide. Leflunomide is an isoxazole 
immunomodulatary agent which inhibits dihydroroate 
dehydorgenase (an enzyme in involved in de novo pyrimidine 
synthesis) and has antiproliferative activity.  The leflunomide is a 
poorly water soluble drug. The poor aqueous solubility of 
leflunomide leads to variable oral bioavailability. [12,13] This limits 
several advantages of the drug with respect to its absorption, 
distribution and therapeutic efficacy. In this study, investigations 
were performed on the possibility of complexation of leflunomide 
with HP-β-CD for improving the solubility and dissolution rate of 
this drug, as well as to characterize the physicochemical 
properties of formed complexes. The complexes with HP-β-CD 
were prepared by different methods such as physical mixture, co-
grinding method and freeze drying method in 1:1 and 1:2 molar 
ratios. The types and the stability constants of the complexation 
were established according to phase solubility studies. The 
differential scanning calorimetry and X-RD were used to 
characterize the solid state of all the products. The dissolution 
properties of the solid complexes were evaluated and compared 
with those of leflunomide alone and of a physical mixture between 
leflunomide and HP-β-CD. 
Material and Methods 
Leflunomide was obtained as gift sample from Aarti Drugs, 
Mumbai, HP-β-CD was obtained as gift sample from Signet 
Chemical Corporation, Pvt. Ltd., Mumbai, India., and the other 
chemicals used are of analytical grade. 
Methods 
Phase Solubility Studies 
Solubility measurements were carried out and the stability 
constants (Ks) of the complex were determined according to the 
phase solubility method of Higuchi and Connors (1965). [14] An 
excess amount of leflunomide was added to 10 ml of aqueous 
solution containing various concentrations of HP-β-CD (0, 2, 4, 6, 
8 and 10 mM) into the glass vials.  The contents were shaken for 
48 hours at room temperature on rotary flask shaker. After 
equilibrium, the samples were withdrawn, filtered through a 
Whatmanpaper and diluted appropriately. A portion of samples 
were analyzed by UV spectrophotometer at 257 nm. The apparent 
stability constant was calculated from the initial straight portion of 
the phase solubility diagram using the following equation: 
              
 Where, 
S = Solubility of drug without cyclodextrin 
M = Molar concentration 
K = Apparent stability constant 
Slope is calculated from regression equation 
Preparation of Solid Inclusion Complexes 
The following solid inclusion complexes of leflunomide with HP-β-
CD were prepared in both 1:1 and 1:2 molar ratios. 
Physical Mixture 
The physical mixtures of leflunomide with HP-β-CD in 1:1 and 1:2 
molar ratios were prepared by simply mixing the powders with a 
spatula. 
Co-grinding Method 
The co-grinding mixture of Leflunomide with HP-β-CD in1:1 and 
1:2 molar ratios were prepared by triturating the powder in glass 
mortar pestle for 20 minutes and passed through sieve no. 85. 
Freeze-drying Method 
The required 1:1 and 1:2 stoichiometric quantity of leflunomide 
was dissolved in methanol and added to an aqueous solution of 
HP-β-CD. The resulting solutions were frozen at 20ĈC for 3 hrs 
and lyophilized in freeze dryer (Benchtop 4.0kïL Freeze Dryer, 
Virtis, USA) maintained at freezing temperature of (-70 to -75ĈC), 
vaccum applied in dried chamber: 75 to 80 mT, at ambient 
temperature (16 to 18.5ĈC). The lyophilized powder was passed 
through a sieve no. 60 and stored in a sealed glass vial. 
Differential Scanning Calorimetry  
The DSC thermograms of pure drug, HP-β-CD, physical mixture, 
co-grinding complex, and freeze dried complex with HP-β-CD 
were recorded. The samples were separately sealed in aluminum 
cells and set in Perkin Elmer (Pyris 1) DSC. The thermal analysis 
was performed in a nitrogen atmosphere over a temperature 
range of 50ĈC to 250ĈC. 
X-Ray Diffraction Spectroscopy 
The X-ray diffraction pattern of pure drug, HP-β-CD, physical 
mixture, co-grinding complex and freeze dried complex with HP-β-
CD were recorded from 5 to 80Ĉ at an angle 2θ using 
diffractometer system. 
In-vitro Dissolution Studies 
The prepared complexes (n = 3) were subjected to release 
studies using USP-II (Paddle) dissolution apparatus at 100 rpm. 
Dissolution medium was used simulated gastric fluid          (SGF 
pH 1.2, 900 ml) and simulated intestinal fluid (SIF pH 7.4, 900 ml) 
maintained at 37μ0.5ĈC. The samples were withdrawn (10 ml) at 
different time intervals and replaced with an equivalent amount of 
fresh medium and analyzed immediately by using UV Visible 
spectrophotometer. The concentration of leflunomide released 
was determined by measuring the absorbance at 257 nm. After 
analyzing the drug content in the dissolution samples, corrections 
were made for the volume replacement and the graph of 
percentage of drug release versus time was plotted.  
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Result and discussion 
 The phase solubility diagram of the complex formation between 
leflunomide with        HP-β-CD is shown in Fig. No.1. This plot 
showed that the aqueous solubility of drug increases linearly as 
the function of HP-β-CD concentration. The phase solubility 
diagram can be classified as type AL, according to Higuchi and 
Connors. It is assumed that the increase in solubility observed 
was due to the formation of a 1:1 M inclusion complex.  The 
stability constant (Ks) of leflunomide with HP-β-CD complex was 
calculated as 224.3 M-1 from the linear plot of the phase solubility 
diagram. 
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Figure 1: Phase Solubility Studies of Leflunomide with HP-β-CD 
Differential Scanning Calorimetry (DSC) 
The thermal behavior of leflunomide with HP-β-CD solid complex 
was studied using DSC in order to confirm the formation of solid 
complexes. The DSC curve of leflunomide and solid inclusion 
complexes are shown in Figure No. 2-9.  
 
 
Figure 2 DSC of Leflunomide 
 
Figure 3 DSC of HP-β-CD 
 
 
Figure 4 DSC of Physical Mixture of Leflunomide with HP-β-CD in 
the ratio of (1:1) 
 
 
Figure 5 DSC of Physical Mixture of Leflunomide with HP-β-CD in 
the ratio of (1:2) 
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Figure 6 DSC of Co-grinding Complex of Leflunomide with HP-β-
CD in the ratio of (1:1) 
 
 
Figure 7 DSC of Co-grinding Complex of Leflunomide with HP-β-
CD in the ratio of (1:2) 
 
 
Figure 8 DSC of Freeze Dried Complex of Leflunomide with HP-
β-CD in the ratio of (1:1) 
 
                                                
 
Figure 9 DSC of Freeze Dried Complex of Leflunomide with HP-
β-CD in the ratio of (1:2)   
                  
 
The DSC curve of leflunomide exhibited a sharp endothermic 
peak at 171.2ĈC corresponding of its melting point. The broad 
endothermic peak at 118.9ĈC was observed for amorphous HP-β-
CD, was related to loss of water molecules i.e. dehydration 
process. In the   thermogram of leflunomide with HP-β-CD the 
height or intensity of endothermic peak of drug was reduced and 
also in inclusion complexes less heat is required during melting 
process as compared to the leflunomide. [15, 16] 
The enthalpy values of the drug, HP-β-CD, physical mixture, co-
grinding complex and  freeze dried complex in 1:1 and 1:2 molar 
ratios are shown in following Table No 1. 
 
Bankar et al. International Journal of Drug Delivery 4 (4) 498-506 [2012] 
 
PAGE | 502 |
 
Table 1: Enthalpy Values of Different Complexes 
 
 
Solid inclusion complex formation was suggested by a decrease 
in enthalpy of fusion when compared to the pure drug and 
physical mixture. As the bound water molecules of cyclodextrin 
cavity are replaced with the drug molecules during complexation, 
the resultant fusion enthalpy is relatively less. It indicates the 
crystallinity of drug is decreases. The similar result was reported 
by other authors. [17, 18] 
 The freeze dried complex in 1:2 molar ratios showed relatively 
much less enthalpy fusion value (’H -22.04) as compared to pure 
drug and other inclusion complexes due to higher inclusion 
formation, which is in conformation with the differential solubility 
technique. 
X-Ray Diffraction studies 
The X-ray diffraction patterns of leflunomide with HP-β-CD in solid 
complexes are shown in Figure No.10-17.   
 
Figure 10 X-RD of Leflunomide 
 
 
Figure 11 X-RD of HP--CD 
 
Sr. 
No. 
Chemicals and Complexes Enthalpy 
(mJ/mg) 
1. Leflunomide 114.46
2. HP-β-CD 134.99
3. Physical mixture of leflunomide  
HP-β-CD in the ratio (1:1) 
42.82
 
4. Physical mixture of leflunomide  
HP-β-CD in the ratio (1:2) 
35.83
 
5. Co-grinding complex  of leflunomide HP-β-CD in 
the ratio (1:1) 
29.42
 
6. Co-grinding complex of leflunomide HP-β-CD in 
the ratio (1:2) 
20.33
7. Freeze dried  complex  of leflunomide HP-β-CD in 
the ratio (1:1) 
(-) 31.34
 
8. Freeze dried  complex  of leflunomide HP-β-CD in 
the ratio (1:2) 
(-) 22.04
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Figure 12 X-RD of Physical Mixture of Leflunomide with HP-β-CD 
in the ratio of (1:1) 
 
 
Figure 13 X-RD of Physical Mixture of Leflunomide with HP-β-CD 
in the ratio of (1:2) 
 
 
Figure 14 X-RD of Co-grinding Complex of Leflunomide with HP-
β-CD in the ratio of (1:1) 
 
Figure 15 X-RD of Co-grinding Complex of Leflunomide with HP-
β-CD in the ratio of (1:2) 
Bankar et al. International Journal of Drug Delivery 4 (4) 498-506 [2012] 
 
PAGE | 504 |
 
 
Figure 16 X-RD of Freeze Dried Complex of Leflunomide with 
HP-β-CD in the ratio of (1:1) 
 
Figure 17 X-RD of Freeze Dried Complex of Leflunomide with 
HP-β-CD in the ratio of (1:2) 
The X-ray diffractometry is a useful tool for the detection of 
cyclodextrin complexation in powder or microcrystalline states. 
[19] The diffractogram of leflunomide exhibits intense lines and 
characteristic peaks which are indicative of their crystallinity. (20) 
The results indicated that the most of peaks of physical mixture 
were the superposition of peaks of leflunomide and       HP-β-CD. 
Partial peaks of leflunomide declined showing that the slight 
complexation may occur in physical mixture and in co-grinding 
complex. Whereas, the X-ray diffraction pattern of freeze dried 
complex of leflunomide with HP-β-CD was completely different 
from that of leflunomide or HP-β-CD, demonstrating that a new 
solid phase formed and showed a more diffuse pattern as 
compared to the other complexes. 
Dissolution studies 
 The in-vitro dissolution profiles of drug and inclusion complexes 
in 1:1 and 1:2 molar ratios in dissolution mediums such as 
simulated gastric fluid (pH 1.2) and simulated intestinal fluid (pH 
7.4) are depicted in Figure No.18-19. The dissolution rate of 
complexes was higher as compared to the pure drug. It was 
observed that the co-grinding method and freeze-dried method in 
1:2 molar ratios showed the increase in dissolution rate compared 
with pure drug and physical mixture. The dissolution profile of co-
grinding complex in 1:2 molar ratio showed 56.63 % drug release 
in 60 min. in pH 1.2 and in pH 7.4 showed 35.18 % drug release 
in 20 min. corresponding to the pure drug. The dissolution profile 
of freeze-dried complex in 1:2 molar ratio showed 89.19 % drug 
release in 10 min. in pH 1.2 and in pH 7.4 showed 77.17 % drug 
release in 10 min. corresponding to the pure drug. The significant 
improved in dissolution characters in case of inclusion complex 
prepared by freeze-dried method with HP-β-CD may be due to 
formation of solid inclusion complex in dissolution media with 
better interaction of drug and HP-β-CD during freeze-dried 
method. And also marked increase in dissolution characters due 
to increase in drug wettability and reduction in crystallinity of drug. 
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Figure 18 Results of Dissolution Profile of Pure Drug, PM, CG, FD 
(1:1) and (1:2) with HP--CD in pH 1.2 
0 10 20 30 40 50 60
0
25
50
75
100
Pure Drug
PM (1:1)
PM (1:2)
CG (1:1)
CG (1:2)
FD (1:1)
FD (1:2)
Time in min.
Pe
rc
en
t R
el
ea
se
 R
at
e
 
Figure 19 Results of Dissolution Profile of Pure Drug, PM, CG, FD 
(1:1) and (1:2) with HP--CD in pH 7.4 
Conclusion 
The solubility and dissolution rate of leflunomide can be increased 
by inclusion complexation with HP-β-cyclodextrin. The phase 
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solubility studies indicated the formation of inclusion complexes 
with HP-β-CD at 1:1 stoichiometric ratio in solution with stability 
constant of 224.3 M-1. The results obtained by different 
characterization techniques clearly indicated that freeze-dried 
method leads to formation of solid state complexes between 
leflunomide and       HP-β-CD in pH 1.2.  The complexation of 
leflunomide with HP-β-CD lends an ample credence for better 
therapeutic efficacy. 
List of abbreviations 
  β-CD  -  Beta-cyclodextrin 
  HP-β-CD -  Hydroxy Propyl Beta-cyclodextrin 
   DSC  -  Differential scanning calorimetry 
  FTIR  -  Fourier transform infrared spectroscopy 
 X-RD  -  X-ray diffraction  
 
AuthorÊs contributions 
Mrs. P.V. Bankar  - Carried out experimental part of study 
Dr. O. P. Mahatma and substantial contribution to conception and 
design, or acquisition of data, or analysis and                   
interpretation of data, also involved in drafting                   
or revising it critically for important intellectual                    
content and given final approval of the version to                   
be published.  
 Acknowledgment 
The authors are grateful to Dr. O.P. Mahatama, Principal of B.N. 
Girls College of Pharmacy, Udaipur, Rajasthan, India, for 
providing technical assistance and support for this study. 
 
 
References 
 
[1]. Patrekar P, Patil C.C. Solubility 
enhancement and evaluation of 
diacerein using cyclodextrin as 
hydrophilic carriers. J. of Pharmacy 
Research. 2009, 2(5), 923-926. 
[2]. Vadav BV, Yadav VA. Enhancement of 
solubility and dissolution rate of BCS 
Class II pharmaceuticals by 
nonaqueous granulation technique. Int. 
J. Pharma. and Research 
Development. 2010, 12, Feb-008. 
[3]. Mayara MD, Keila AF, Iára CS, Sacha 
KS, Marcos ASS and Patrik OR. 
Physicochemical properties and 
dissolution studies of dexamethasone 
acetate-β-cyclodextrin inclusion 
complexes produced by different 
methods. AAPS PharmSciTech. 2008, 
9(1). 
[4]. Shukla V, Masareddy R, Anghore A, 
Manvi FV. Influence of β-cyclodextrin 
complexation on ketoprofen release 
from matrix formulation‰ Int. J. of 
Pharmaceutical Sciences and Drug 
Research. 2009; 1(3): 195-202.   
[5]. Challa R, Ahuja A, Ali J and Khar RK. 
Cyclodextrins in drug delivery: An 
updated review. AAPS PharmSciTech. 
2005; 6 (2) Article 43 
(http://www.aapspharmscitech.org). 
[6]. Loftsson T, Duchene D. Cyclodextrins 
and their pharmaceutical applications, 
Int. J. of Pharmaceutics. 2007, 329,1-
11. 
[7]. Szejtli J. Past, present and future of 
cyclodextrin research. Pure Appl. 
Chem.2004, Vol. 76, No. 10, 1825-
1845. 
[8]. Nalluri BN, Chowdary KPR, Murthy 
KVR, Hayman AR and Becket G. 
Physicochemical characterization and 
dissolution properties of nimesulide-
cyclodextrin binary systems. AAPS 
PharmSciTech. 2003; 4 (1) Article 2, 1-
2, (http://www.pharmscitech.org). 
[9]. Loftsson T, Jarho P, Masoon M and 
Jarvinen T. Expert Opin. Drug Deliv. 2, 
2003, 335-351.  
[10]. Uekama K, Hirayama F and Irie T. 
Cyclodextrin drug carrier systems. 
Chem. Rev.1998. 98:2045-2076. 
[11]. Rawat S, Jain SK. Solubility 
enhancement of celecoxib using β-
cyclodextrin inclusion complexes. Eur. 
J. of Pharmaceutics and 
Biopharmaceutics. 2004, 57, 263-267. 
[12]. Rang HP, Dale MM, Ritter JM, Moor 
PK. Pharmacology, Churchill 
Livingstone, 5th edition, 2003, 257. 
[13]. www.drugbank.com 
[14]. Higuchi T, Connors A. Phase-solubility 
techniques. In: Advances in analytical 
chemistry instrumentation, New York, 
NY: Wiley Interscience ; 1965; 117-
211. 
[15]. Chowdary KPR and Srinivas SV. 
Influence of hydrophilic polymers on 
celecoxib complexation with 
hydroxypropyl-β-cyclodextrin. AAPS 
PharmSciTech 2006; 7 (3) Article 79 
(http://www.aapspharmscitech.org). 
[16]. Talegaonkar S, Khan AY, Khar RK, 
Ahmad FJ and Khan ZI. Development 
and characterization of paracetamol 
complexes with hydroxypropyl-β-
cyclodextrin. Iranian J. of 
Pharmaceutical Research, 2007, 6 (2): 
95-99. 
[17]. Kalaiselvan R, Mohanta GP, Manna 
PK, Manavalan R. Multicomponent 
system of albendazole with 
cyclodextrins and hydroxyacids. Acta 
Pharmaceutica Sciencia. 2006, 48: 19-
33. 
[18]. Patel HM, Suhagia BN, Shah SA, 
Rathod IS, Parmar VK. Preparation and 
characterization of etoricoxib-β-
cyclodextrin complexes prepared by the 
Bankar et al. International Journal of Drug Delivery 4 (4) 498-506 [2012] 
 
PAGE | 506 |
 
kneading method. Acta Pharm. 2007, 
57, 351-359.         
[19]. Wan-Liang LU, Qiang Z, Li Z, Hua W, 
Rong-Yu LI, Li-Feng Z, Wen-Bin S and 
Xi-De T. Antipyretic, Analgesic and 
Anti-inflammatory Activities of 
Ketoprofen β-cyclodextrin inclusion 
complexes in animals. Biol. Pharm. 
Bull. 2004, 27(10) 1515-1520.  
[20]. Moyano JR, Arias-Blanco MJ, Gines 
JM, Giordano F. Solid-state 
characterization and dissolution 
characteristics of gliclazide-β-
cyclodextrin inclusion complexes. Int. J. 
of Pharmaceutics.1997, 148, 211-217.    
 
 
